[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590480":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":42,"collaborators":18,"id":44,"slug":18,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":18,"enrollmentInfo":52,"targetDuration":18,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":70,"overallStatus":28,"whyStopped":18,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Institut Claudius Regaud","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Patients with metastatic cancer","* Blood sample collection for circulating DP cell detection by flow cytometry and Cell Search analysis for the following patients:\n\n  * Cohort 1 : urothelial carcinoma\n  * Cohort 2 : renal carcinoma\n  * Cohort 3 : prostate adenocarcinoma\n  * Cohort 4 : upper aerodigestive tract carcinoma\n  * Cohort 5 : cervical carcinoma\n  * Cohort 6 : adenocarcinoma of endometrium\n* Blood sample collection for circulating DP cell detection by flow cytometry and Parsotix analysis for the following patients:\n\n  * Cohort 7 : cutaneous melanoma\n  * Cohort 8 : soft tissue sarcoma\n  * Cohort 9 : seminomatous and nonseminomatous germ cell tumors",[12],"Other: For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:","A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Thibaud VALENTIN, MD","CONTACT","0033 5 31 15 51 70","valentin.thibaud@iuct-oncopole.fr",[26],{"facility":27,"status":28,"city":29,"state":18,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Oncopole Claudius Regaud, IUCT-O","RECRUITING","Toulouse","31059","France",{"type":33,"coordinates":34},"Point",[35,36],1.44367,43.60426,{"lat":36,"lon":35},[39,40],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},{"name":21,"role":41,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"type":43,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100590480",false,"NCT06967961","Research of Double-positive Circulating Cells (Tumor Marker \u002F CD45+) in Several Types of Metastatic Cancers","DP-PAN-CANCER","Inclusion Criteria:\n\n* 1\\. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors\n* 2\\. Metastatic disease for which the treatment (whatever the line) has not been initiated yet\n* 3\\. Age ≥ 18 years\n* 4\\. Patient affiliated to a French Social Security scheme\n* 5\\. Patient having signed his\u002Fher informed consent prior to inclusion in the study and prior to any specific procedure for the study.\n\nExclusion Criteria:\n\n* 1\\. Patient with localized disease.\n* 2\\. Pregnant or breast-feeding women.\n* 3\\. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and\u002For procedures set out in the study protocol.\n* 4\\. Patient who has forfeited his\u002Fher freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).","ALL","18 Years",{"count":53,"type":54},450,"ESTIMATED","INTERVENTIONAL",[57],"NA","A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis.\n\nEach patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer.\n\n450 patients will be enrolled in total.",[60,61,62,63,64,65,66,67,68,69],"Urothelial Carcinoma","Renal Cancer","Prostate Adenocarcinoma","Adenocarcinoma of Endometrium","Cutaneous Melanoma","Soft Tissue Sarcoma (STS)","Nonseminomatous Germ Cell Tumor","Seminomatous Germ Cell Tumor","Upper Aerodigestive Tract Carcinoma","Cervical Carcinoma",[71,72,73],"metastatic cancers","Double Positive Circulating cells","liquid biopsy","2026-06-12",{"date":76,"type":77},"2026-06-15","ACTUAL",{"date":79,"type":77},"2025-07-23",{"date":81,"type":54},"2029-07-23",{"name":5,"class":6},1]